新型生物标志物在心源性休克风险评估和预后预测中的作用研究进展

Research progress on the role of new biomarkers in risk assessment and prognosis prediction of cardiogenic shock

心源性休克(CS)病情进展快、死亡率高,需要快速识别和处理高风险患者,血浆生物标志物的检测有助于CS患者的早期风险识别,从而优化治疗措施。近年来,新的CS生物标志物在休克进展、病程监测和死亡风险预测中的作用受到临床关注,这些标志物包括与炎症、免疫、内皮功能相关的标志物以及基于蛋白质组学筛选的标志物等。本文对几种CS新型生物标志物在休克风险评估和预后预测中的作用研究进展进行综述。

Cardiogenic shock(CS)is characterized by rapid progression and high mortality,which requires rapidly identification and management of the high-risk patients.The detection of plasma biomarkers is helpful for early risk identification of CS patients,so as to optimize treatment measures.In recent years,the role of new CS biomarkers in shock progression,disease course monitoring and death risk prediction has attracted clinical attention.These biomarkers include markers related to inflammation,immunity,endothelial function,and markers based on proteomics screening.This article reviews the research progress of several novel biomarkers of CS in shock risk assessment and prognosis prediction.